One prospective multicenter study to investigate the resistance mechanisms in patients with advanced NSCLC who progressed after ALK inhibitors demonstrated heterogeneous mechanisms of resistance, including the loss of ALK mutations in less than one-third of cases, in addition to various compound ALK mutations, and bypass mutations [78]. Here, ALK is linked to non-small cell lung carcinoma.